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EC = endothelial cell; IBC = inflammatory breast cancer; MRA = magnetic resonance angiography; VEGF = vascular endothelial growth factor; VM
= vasculogenic mimicry.
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Introduction
Growth, proliferation, and metastasis of breast cancer,
and of most other tumors, have been thought to be angio-
genesis-dependent processes [1]. However, a non-angio-
genesis-dependent pathway, in which tumors can feed
themselves using alternative pathways, has also been
reported [2–12]. Previously, we and others described the
presence of vasculogenic mimicry (VM, a condition in
which tumors [inflammatory breast cancer {IBC} and
melanoma] feed themselves using alternative pathways
without the participation of endothelial cells [ECs]) in the
tumor-bearing state. In the present study, we established
a new human IBC xenograft (WIBC-9) in BALB/c nude
mice and investigated the hemodynamics of VM and
angiogenesis of IBC, using WIBC-9 xenografts and
dynamic micro-magnetic resonance angiography (micro-
MRA) analysis. The unique patterns characteristic of VM
and its hemodynamics provide a framework for the design
of non-invasive imaging techniques for detecting IBC and
its metastases.
Method
Morphological and chromosomal analysis
The animal protocols for all experiments were approved by
the Animal Use Committee of the National Cancer Center.
Hematoxylin–eosin and Giemsa staining of paraffin-embed-
ded specimens were performed, as were electron micro-
scopic examinations following a conventional method. For
karyotype studies of the xenograft, the Giemsa G banding
method was performed after 6 and 12 passages.
Dynamic micro-MRA with an intravascular contrast agent
We performed dynamic micro-MRA analysis, using our
newly developed intravascular macromolecular contrast
agent for magnetic resonance imaging, which consistently
showed no significant leakage through the vascular wall
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Abstract
We recently established a new human inflammatory breast cancer (IBC) xenograft (WIBC-9)
originating from a patient with IBC. The original tumor and WIBC-9 revealed invasive ductal carcinoma
with a hypervascular structure of solid nests and marked lymphatic permeation in the overlying dermis.
In the central part of the solid nests, vasculogenic mimicry, which showed an absence of endothelial
cells, was observed. Comparison of WIBC-9 with an established non-IBC xenograft (MC-5), using
time-course dynamic micro-magnetic resonance angiography analysis (with a newly developed
intravascular macromolecular contrast agent for magnetic resonance imaging) demonstrated that the
WIBC-9 tumor had blood flow and a vascular mimicry–angiogenesis junction.
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after remaining in circulation for more than 30 min, to eval-
uate the physiological properties of the vascular channels
in the xenografted tumors [13]. We used female 8-week-
old BALB/c nude mice bearing either WIBC-9 or MC-5
tumor xenografts. This procedure was performed with
mice bearing WIBC-9 and MC-5 tumors (n=3, for each). 
Results
Establishment of WIBC-9 tumors
The surgically resected tumors from 10 patients with IBC
(Fig.1A) were transplanted into BALB/c nude mice. The
tumor from the ninth patient, referred to as WIBC-9,
induced erythema in the overlying skin (Fig.1B), thus
showing the features of IBC. Histologically, WIBC-9 grew
locally in an expansive manner, forming a solid nest struc-
ture and exhibiting marked lymphatic permeation. In the
center of the solid nests, the tumor exhibited a lack of
endothelial formation but without central necrosis
(Fig.1C,D). Transmission and phase-contrast electron
microscopy clearly showed blood pooling without a lining
of ECs in the center of the tumor nests (Fig.1E,F). There
was no vascular structure between the surrounding tumor
cells and erythrocytes. Neither necrosis nor fibrosis was
observed in the tumor nest. The VM surrounding tumor
cells was positive for Flt-1 (vascular endothelial growth
factor [VEGF] type 1 receptor) and Tie-2 (angiopoietin-1,2
receptor) (Fig.1G,H). Our data on the clinical oncology of
VM in IBC showed that these are key genes in expressing
VM formation. This phenotype remained stable for more
than 15 transplant generations. A karyotype analysis
revealed chromosomal abnormalities in terms of structure
and number. The median chromosome number was 75
(range 72–77) and there was aneuploidy (n=20) (Fig.1I).
Time-course MRA of WIBC-9 and MC-5 tumors
Time-course micro-MRA (Fig.2) was performed to analyze
hemodynamics in the VM (central tumor) and angiogenesis
(marginal tumor) regions. The images were acquired before
injection of the contrast agents and 1, 2, 3, 5, 10, 15, and
30 min after injection. The marginal region of WIBC-9 and
MC-5 tumors exhibited a signal that gradually increased in
intensity, a result somewhat consistent with the intensity
recorded for lung and heart. This explained the connection
between neovascular and preexisting vessels and their
hemodynamics. In the tumor center, WIBC-9 tumors exhib-
ited spots in which the signal gradually increased in inten-
sity (which is consistent with the intensity observed at their
tumor margin), whereas MC-5 tumors exhibited a lack of
signal in association with central necrosis. This might
explain the connection between VM and neovascular activ-
ity surrounding tumor cells.
Hemodynamics of VM and angiogenesis of IBC and
non-IBC xenografts
To analyze hemodynamics in VM and angiogenesis (blood
flow through newly established, EC-lined blood vessels),
we focused on three regions of interest in the central area
and the marginal area of the xenografted tumors, and mea-
sured the change in numbers of white pixels per mm2
(Fig.3). The time course of intensity of the tumor center
(corresponding to the hemodynamics of VM) was broadly
consistent with the time course of intensity of the tumor
margin (corresponding to the hemodynamics of angiogen-
esis). Examination of the hemodynamics of VM revealed
blood flow with two peaks of intensity and a statistically
Figure 1
Morphological and chromosomal analysis. (A) Histological features of
the human original tumor revealed invasive ductal carcinoma and blood
pooling without a lining of endothelia. (B) Characteristic appearance of
the tumor at the site of subcutaneous inoculation. (C,D) Microscopic
analysis of WIBC-9 stained with hematoxylin–eosin (C) and Giemsa
(D) revealed hypervascularity, blood pooling without a lining of EC and
no central necrosis or fibrosis in the center of the tumor nest. (E)
Transmission electron microscopy revealed the interface between
tumor cells and erythrocytes. (F) Phase-contrast electron microscopy
clearly visualized erythrocytes between tumor cells. Erythrocytes
appeared black. (G,H) Vasculogenic mimicry surrounding tumor cells
was positive for Flt-1 (G) and Tie-2 (H). (I) Karyotype analysis of
WIBC-9 revealing aneuploidy and marked chromosomal abnormalities.138
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significant time lag relative to the hemodynamics of angio-
genesis. The rate of tumor margin angiogenesis in
WIBC-9 xenografts was at least threefold that observed in
MC-5.
Discussion
The established xenograft WIBC-9 preserves the histolog-
ical and biological characteristics of human IBC. The fea-
tures of erythema in the overlying skin, marked lymphatic
permeation and high rate of metastasis are commonly
seen in both WIBC-9 and human IBC. WIBC-9 has two
unique histological features: blood pooling without a lining
of ECs. Electron microscopy revealed the interface of
tumor cells and erythrocytes lacking both necrosis and
fibrosis. These structures exhibited weak expression of the
human activated EC marker, human integrin αvβ3. These
structures are lined externally with tumor cells and no ECs
are seen. These results suggest the de novo formation of
vascular channels by tumor cells in the central tumor
under putative hypoxia and induced angiogenic factors.
They also suggest that vessel regression has not been
occurring in these tumors and that the blood from rup-
tured vessels has not filled tumor-lined lakes or channels.
WIBC-9 exhibited no fibrosis, central necrosis, or lining of
endothelia, whereas other breast cancer xenografts com-
monly exhibit fibrosis and central necrosis as the tumor
grows. We believe these findings might be related to the
expression of certain genes in WIBC-9 (i.e. huFlt-1,
huTie-2,  huTie-1, and huIntegrinαvβ3) [14]. This gene
expression might result in the observed endothelial/vascu-
lar phenotype and the putative de novo formation of the
vascular channel by tumor cells. In the tumor margin,
WIBC-9 exhibited hypervascularity and also significantly
more intense immunoreactivity of murine CD31 in the neo-
vascular epithelia than did non-IBC xenografts. This might
explain the endothelial sprouting of new vessels from pre-
existing vessels as a result of overexpression of the angio-
genic factors.
Figure 2
Time-course magnetic resonance angiography of WIBC-9 and MC-5 tumors. The images were acquired before the injection of the contrast agents
(pre) and 1, 2, 3, 5, 10, 15, and 30 min after injection. The tumor marginal area of both WIBC-9 and MC-5 exhibited a signal that gradually
increased in intensity. In the tumor center, WIBC-9 exhibited spots in which the signal gradually increased in intensity (consistent with the intensity
recorded for the tumor margin), whereas the central region of MC-5 maintained a lack of signal.
Figure 3
Hemodynamics in vasculogenic mimicry of inflammatory breast cancer
(IBC) xenografts and angiogenesis of IBC and non-IBC xenografts. All
data are expressed as means±SD. The time course of intensity of the
tumor center (corresponding to the hemodynamics in vasculogenic
mimicry) was consistent with the time course of intensity of the tumor
margin (corresponding to the hemodynamics of angiogenesis). The
degree of tumor margin angiogenesis in WIBC-9 tumors was at least
threefold that observed in MC-5.139
We have previously proposed an angiogenic pathway and
a non-angiogenic pathway (VM), and focused on the rela-
tionship between the migration of ECs (including endothe-
lial precursor cells) and de novo vascular channel
formation associated with tumor cells [4]. In particular, we
focused on the VEGF-Flt-1 and angiopoietin-1,2–Tie-2
pathway based on the clinical oncological data derived
from a cDNA array analysis of VM cases and non-VM
cases. When these pathways were blocked by the injec-
tion of adenovirus vectors encoding specific anti-angio-
genic agents (sFlt-1 and sTie2) into WIBC-9 tumors, the
formation of VM ceased [5]. The results of our recent
studies demonstrated that six established human breast
cancer lines, particularly the IBC line WIBC-9, induce
postnatal endothelial precursor cell kinetics as well as EC
kinetics [6,7].
In the present study we investigated the existence of VM
and its hemodynamics in the IBC xenograft WIBC-9. In
particular, we may have demonstrated the existence of a
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